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Abstract
Objective To model the long term effectiveness and cost effectiveness
of daily dark chocolate consumption in a population with metabolic
syndrome at high risk of cardiovascular disease.
Design Best case scenario analysis using a Markov model.
Setting Australian Diabetes, Obesity and Lifestyle study.
Participants 2013 people with hypertension who met the criteria for
metabolic syndrome, with no history of cardiovascular disease and not
receiving antihypertensive therapy.
Main outcome measures Treatment effects associated with dark
chocolate consumption derived from published meta-analyses were
used to determine the absolute number of cardiovascular events with
and without treatment. Costs associated with cardiovascular events and
treatments were applied to determine the potential amount of funding
required for dark chocolate therapy to be considered cost effective.
Results Daily consumption of dark chocolate (polyphenol content
equivalent to 100 g of dark chocolate) can reduce cardiovascular events
by 85 (95% confidence interval 60 to 105) per 10 000 population treated
over 10 years. $A40 (£25; €31; $42) could be cost effectively spent per
person per year on prevention strategies using dark chocolate. These
results assume 100% compliance and represent a best case scenario.
Conclusions The blood pressure and cholesterol lowering effects of
dark chocolate consumption are beneficial in the prevention of
cardiovascular events in a population with metabolic syndrome. Daily
dark chocolate consumption could be an effective cardiovascular
preventive strategy in this population.
Introduction
Cardiovasculardiseaseistheleadingcauseofdeathworldwide,
with the death rate estimated at 17.5 million in 2004 (29% of
all deaths).
1 The metabolic syndrome describes a cluster of risk
factors that significantly increase the risk of developing
cardiovascular disease and diabetes,
2 and the syndrome is
becomingincreasinglyprevalentowingtorisingratesofobesity
and diabetes and an aging population. Lifestyle changes such
as dietary modifications and behavioural adaptations constitute
firstlinetreatmentinthepreventionofdiseasesassociatedwith
the metabolic syndrome. Dietary modifications that increase
theintakeofvegetables,fruit,andgrainsanddecreasetheintake
of saturated fats and refined sugars are recommended. It is
believed that the high content of polyphenolic antioxidants in
some fruit, vegetables, whole grains, nuts, and tea may
contribute to their cardioprotective effects.
3 Dark chocolate,
derived from cocoa beans, is another food rich in polyphenols,
specifically flavonoids. Flavonoids exhibit antihypertensive,
anti-inflammatory,antithrombotic,andmetaboliceffects,allof
which may contribute to their protective effect.
4
Several recent studies have suggested that the consumption of
darkchocolatemayhavebloodpressureloweringeffects.
5 6The
mechanisms for these effects remain under investigation, but
flavanols have been shown to stimulate the production of
endothelialnitricoxide,causingbloodvesselstodilateandthus
lowering blood pressure.
7 8 A recent meta-analysis showed that
a diet high in cocoa rich products significantly reduced blood
pressure in both hypertensive and prehypertensive states.
9
Studiesexploringtheeffectofdarkchocolateonbloodpressure
thusfarhavebeenrelativelyshort,withamaximumintervention
period of 18 weeks in the studies contributing to a recent
meta-analysis.
10
Dark chocolate consumption has also been suggested to have
lipid modifying effects, decreasing total and low density
lipoprotein cholesterol levels and increasing high density
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11 However, these changes have
also only been explored in short term trials, lasting 2-18 weeks.
Thelogisticaldifficultiesandconsiderableexpenseoflongterm
placebo controlled clinical trials of dietary components mean
it is unlikely that high level evidence linked to cardiovascular
diseaseoutcomewillbeobtainedinthenearfuture.Weutilised
available data and statistical modelling techniques to estimate
the long term effects and associated cost effectiveness, from a
healthcare system perspective, of dark chocolate consumption
in a population with metabolic syndrome at high risk of
cardiovascular disease.
Methods
We constructed a Markov model
12 to assess the health effects
and associated costs of daily consumption of plain dark
chocolate compared with no chocolate in a population with
metabolic syndrome without diabetes and initially without
cardiovascular disease. The figure⇓ depicts the health states
included in the model: “alive without cardiovascular disease,”
“alive with cardiovascular disease,” “dead from cardiovascular
disease,” and “dead from other causes.” We used decision
analysis
13 to compare two health strategies: no dark chocolate
(control) with dark chocolate (treatment). The perspective
adopted was that of the Australian healthcare system.
All individuals entered the model in the initial health state of
being alive without cardiovascular disease. With each annual
cycle, we used risk prediction algorithms and population life
tablestodeterminetheprobabilityofanindividualtransitioning
to the other health states—that is, developing non-fatal
cardiovascular disease or dying from cardiovascular disease or
non-cardiovascular causes. All events were assumed to occur
halfwaythroughacycle.Individualscontinuedtocyclethrough
the model, with more and more moving into diseased or dead
states as the period of follow-up increased, until the period of
interest (10 years) was reached or death occurred.
In any cycle, we generated random numbers of between 0 and
1.0 to determine if any event occurred. For example, the 100th
person in our model was a 44 year old, non-smoking male,
whosebaselinecharacteristicswere:systolicbloodpressure143
mmHg,totalcholesterolconcentration7.0mmol/L,highdensity
lipoprotein cholesterol concentration 1.0 mmol/L, glycated
haemoglobin (HbA1c) 32.2 mmol/mol, body mass index 33.9,
and absence of diabetes. In the first cycle (year 1), his
probabilityofanon-fatalcardiovasculareventwas0.27%,fatal
cardiovasculareventwas0.006%,andnon-cardiovascularfatal
event was 0.15%. The random number generated for this man
in cycle 1 was 0.046. He was therefore assumed to have
experienced a non-fatal cardiovascular event and was
subsequently moved to the health state of being alive with
cardiovascular disease for the start of cycle 2. Had the random
number been between 0.27 and 0.27+0.006%, he would have
been assumed to have experienced a fatal cardiovascular event
and moved to the health state of dead from cardiovascular
disease. Had the random number been between 0.27+0.006%
and0.27+0.006%+0.15%,hewouldhavebeenassumedtohave
experienced a non-cardiovascular fatal event and moved to the
health state of dead from other causes. Had the random number
been greater than 0.27+0.006%+0.15%, he would have been
assumed to have survived the cycle without a cardiovascular
eventandbeenreturnedtothehealthstateofbeingalivewithout
cardiovascular disease.
Modelled population and subject data
The population used in the model comprised participants
selected from the Australian Diabetes Obesity and Lifestyle
(AusDiab) study, among whom cardiovascular risk was
estimated individually. Detailed descriptions of the Australian
Diabetes, Obesity and Lifestyle study have been published
elsewhere.
14 Only participants free of cardiovascular disease or
diabetes,orboth,atbaseline,andclassifiedashavingmetabolic
syndrome according to the joint interim guidelines
15 (published
in2009)wereincludedinthemodel.Thejointinterimguidelines
define metabolic syndrome on the basis of three of five risk
factors:increasedwaistcircumferencewithpopulationspecific
and country specific definitions; triglyceride concentrations
≥150 mg/dL (1.7 mmol/L) or drug treatment for increased
triglyceride levels; high density lipoprotein cholesterol
concentration<40mg/dL(1.0mmol/L)inmalesand<50mg/dL
(1.3 mmol/L) in females, or drug treatment for reduced high
density lipoprotein cholesterol levels; systolic blood pressure
≥130 mm Hg or diastolic blood pressure ≥85 mm Hg or both,
ortreatmentforhypertension;andfastingglucoseconcentration
≥100mg/dLordrugtreatmentforincreasedglucoselevels.We
also excluded those who were receiving antihypertensive
therapy.
Risks of cardiovascular disease and death
WeusedFraminghamalgorithms
16tocalculatethebaselinerisk
of non-fatal cardiovascular disease, comprising myocardial
infarction and stroke, as well as cardiovascular death. These
risks were calculated according to individual specific data on
age, sex, systolic blood pressure, total cholesterol level, high
density lipoprotein cholesterol level, smoking status, presence
or absence of diabetes, and presence or absence of left
ventricularhypertrophy.Witheachannualcyclewerecalculated
cardiovascular risk according to increases in age and expected
changes in systolic blood pressure, total cholesterol level, and
high density lipoprotein cholesterol level. Age and sex specific
changes to blood pressure and lipid levels were determined
according to baseline data stratified by sex and five year age
bands.Fromthesewederivedannualchangeswithinagebands.
We assumed all changes to be linear.
We calculated the risk of death among people with
cardiovascular disease using one year mortality data from the
ReductionofAtherothrombosisforContinuedHealth(REACH)
registry.
17 This prospective cohort study followed people with
at least three atherothrombotic risk factors or a history of
atherothrombotic disease, or both, for a period of two years,
collecting data on morbidity and mortality. As mortality data
from the Reduction of Atherothrombosis for Continued Health
registry were not specified for subgroups, we made the
assumption that all people with cardiovascular disease shared
the same risks of death.
Wecalculatedtherisksofdyingfromnon-cardiovascularcauses
using national long term, age and sex specific mortality data
fromAustralia.
18Themostrecentavailabledatawerefrom2007.
Owing to lack of data stratified by history of cardiovascular
disease, we made the assumption that the data were the same
for participants with and without cardiovascular disease.
Treatment benefit
Changes in cardiovascular risk associated with the treatment
arm were calculated by application of expected effects of dark
chocolate on systolic blood pressure and lipid levels. Data on
the blood pressure lowering effects of dark chocolate
consumption were gathered from a meta-analysis of 13
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cocoa on blood pressure.
9 All trials were longer than 14 days
but heterogeneous for levels of flavonoids (range 30-1008
mg/day) administered in various forms (table ⇓). This
meta-analysis found that cocoa products rich in flavonols, such
as dark chocolate, had a blood pressure lowering effect
compared with the control (systolic blood pressure −3.2 mm
Hg, 95% confidence interval −5.1 to −1.2 mm Hg, P=0.001;
diastolic blood pressure −2.0 mm Hg, −3.4 to −0.7 mm Hg,
P=0.003). When participants were stratified according to
hypertension,bloodpressurewassignificantlyreducedinthose
with hypertension (systolic blood pressure −5.0 mm Hg, −8.0
to −2.1 mm Hg, P<0.001; diastolic blood pressure −2.7 mm
Hg,−4.9to−0.6mmHg,P=0.01),butnotsignificantlyreduced
in those in a normotensive state (systolic blood pressure −1.6
mm Hg, −3.8 to 0.7 mm Hg, P=0.17; diastolic blood pressure
−1.3mmHg,−2.9to0.3mmHg,P=0.12).Someheterogeneity
existed among the treatment effects observed between trials
(systolic blood pressure I
2=74%; diastolic blood pressure
I
2=62%). This remained high in the hypertensive subgroup
(I
2=90%; I
2=79%) but was reduced in the normotensive state
(I
2=23%; I
2=24%).
Effects of dark chocolate consumption on lipid profiles were
informed by a meta-analysis of eight short term trials
investigating the effect of cocoa on healthy participants (table
1).
11 It showed that short term (2-18 weeks) consumption of
dark chocolate decreased low density lipoprotein cholesterol
concentrations (−0.15 mmol/L, 95% confidence interval −0.29
to −0.02 mmol/L, P=0.03) but had no significant effect on total
cholesterol concentrations (−0.15 mmol/L, −0.32 to 0.02
mmol/L, P=0.08) or high density lipoprotein cholesterol
concentration (0.03 mmol/L, −0.07 to 0.13 mmol/L, P=0.56).
Subgroupanalysesaccordingtohealthstatus,however,showed
thatdarkchocolateconsumptioncouldsignificantlyreduceboth
total cholesterol and low density lipoprotein cholesterol levels
in those with high cardiovascular risk (total cholesterol 0.21
mmol/L, 95% confidence interval −0.35 to −0.06 mmol/L,
P=0.007; low density lipoprotein cholesterol −0.20 mmol/L,
−0.38 to −0.01 mmol/L, P=0.04). In subgroup analyses, high
density lipoprotein cholesterol levels did not change
significantly.
Table2⇓summarisesthetreatmenteffectsassumedinthemodel.
Costs
Costs of cardiovascular events were taken from a review on the
costofcardiovascularcomplicationsina“healthy”population.
19
They are summarised in table 2. Costs included direct costs of
myocardial infarction and stroke, measured for the first year of
the event and after the first year. We took the cost of a fatal
cardiovascular event from an economic analysis of chronic
diseases in Australia.
20
All costs were inflated to reflect 2012 costs according to the
Australian national health price index.
21
Outcome measures
The outcomes of interest were number of events prevented,
number of life years saved, and potential monies available for
preventionstrategiesprovidedtheincrementalcosteffectiveness
ratios met arbitrary thresholds, in terms of Australian dollars
per year of life saved. We calculated the number of deaths
prevented, by determining the difference in number of deaths
between those consuming and not consuming dark chocolate.
Similarly, we calculated the years of life saved by determining
the number of life years gained from dark chocolate
consumption compared without.
We calculated incremental cost effectiveness ratios by
comparing the difference in net costs between treatment (a diet
rich in cocoa products) and no treatment (control), divided by
the difference in years of life lived by each cohort. The time
horizon of the modelled analysis was 10 years.
Allfuturebenefits(yearsoflifelived)andcostswerediscounted
at 5% per annum.
22 All analyses were also done using
compliance levels of 80%, 90%, and 100%.
Probabilistic sensitivity analyses
Probabilistic sensitivity analyses
23 were undertaken using 95%
confidence intervals surrounding the point estimates for blood
pressure lowering effect and lipid change and 10% uniform
distributions around cost inputs. We assessed the effects of the
uncertaintysurroundingpointestimatessimultaneouslyby1000
iterations of Monte Carlo simulation.
24 Table 2 outlines the
uncertainty ranges applied to key model inputs.
Results
Overall,3069participants(27.3%)fromtheAustralianDiabetes,
ObesityandLifestylestudywereclassifiedashavingmetabolic
syndromeaccordingtothejointinterimstatementformetabolic
syndrome published in 2009, and free of diagnosed
cardiovasculardiseaseorfrankdiabetes.Ofthese,1056(34.4%)
were receiving antihypertensive therapy or had systolic blood
pressures below 121 mm Hg. With these excluded, a total of
2013 (65.6%) participants were included in our model. Table
3⇓ summarises the characteristics of the modelled population.
Thecohortwasrelativelyyoung,withameanageof53.6years.
Because this was a high risk population and selected for
hypertension, the cohort had increased blood pressure (mean
systolicbloodpressure141.1mmHg),cholesterollevels(mean
total cholesterol 6.1 mmol/L), glucose levels (mean HbA1c 34.4
mmol/mol), and waist circumference (mean 100.4 cm).
Table 4[t4] summarises the results of the base case and
probabilistic sensitivity analyses. With 100% compliance, dark
chocolate consumption could potentially prevent 70 non-fatal
(interquartile range 55-85) and 15 fatal (5-20) cardiovascular
events per 10 000 population treated over 10 years. The
estimated incremental cost effectiveness ratio was $A50 000
(£31 150; €38 555; $52 500) per years of life saved when $A40
(interquartile range $A29-55; $42, $31-58) per person per year
was assumed to have been spent on a prevention strategy using
dark chocolate.
When compliance levels were reduced from 100% (best case)
to 90%, the number of non-fatal and fatal events potentially
preventable was reduced to 60 (interquartile range 50-80) and
10 (5-20) per 10 000 population treated over 10 years,
respectively. When compliance levels were further reduced to
80%, the equivalent figures were 55 (40-70) and 10 (5-20). The
potential monies available for prevention strategies per person
for the incremental cost effectiveness ratios to be considered
cost effective were estimated at $A37 (interquartile range
$A26-51;$39,$27-54)when90%ofindividualscompliedwith
dark chocolate consumption and $A32 ($A22-45; $34, $23-47)
when 80% complied.
Discussion
Dailyconsumptionofdarkchocolatefor10yearsinapopulation
with metabolic syndrome that was free of diabetes and
cardiovascular disease at baseline and classified as being
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prevention of cardiovascular events. The blood pressure and
cholesterol lowering properties associated with dark chocolate
consumption could potentially prevent 70 (interquartile range
55-85) non-fatal (defined as non-fatal stroke and non-fatal
myocardial infarction) cardiovascular events and 15 (5-20)
cardiovascularrelateddeathsper10000populationtreatedover
10 years. To our knowledge this is the first study to model the
long term effects of dark chocolate consumption in reducing
cardiovascular risk.
Assuming that $A40 ($42) is spent per person per year on a
dark chocolate prevention strategy in this population, the
strategy would be cost effective (based on the commonly
accepted, albeit arbitrary, threshold of $50 000 per years of life
saved
25). The $A40 per person per year could be devoted to
advertising,educationalcampaigns,orpotentiallysubsidisation
of dark chocolate in this high risk population.
Analyses of lower compliance levels indicated that although
the number of preventable non-fatal and fatal cardiovascular
events would be reduced, the incremental cost effectiveness
ratios remained below accepted cost effective thresholds.
Therefore, even if only 80% of individuals with metabolic
syndrome were compliant with the daily consumption of dark
chocolateover10years,itcouldstillbeconsideredaneffective
and cost effective intervention strategy.
Only non-fatal stroke and non-fatal myocardial infarction were
exploredinthisanalysis,andthepotentialeffectivenessofdark
chocolate consumption on other cardiovascular events, such as
heart failure, were not assessed. It is also important to note that
the cardiovascular protective effects of cocoa, and more
specifically flavonoids, have only been shown for dark
chocolate, rather than for milk or white chocolate. This is
possiblyaresultofhigherlevelsofflavonoidsindarkchocolate
and an inhibitory effect in the absorption of flavonoids found
in the milk varieties as a result of interactions of milk proteins.
26
Thereforeanyeffectsshowninthisanalysispertainspecifically
todarkchocolate(orequivalentamountsofcocoaorpolyphenol
enriched chocolate).
Comparison with other studies
The effects of dark chocolate consumption on blood pressure
and total cholesterol, although beneficial, are not as profound
as those of drug interventions. A meta-analysis
27 found that
bloodpressureloweringdrugscanreducesystolicbloodpressure
by 9.1 mm Hg at a standard dose and 7.1 mm Hg at a half dose.
TheStatinTherapiesforElevatedLipidLevelscomparedAcross
doses to Rosuvastatin (STELLAR) trial
28 estimated that statins
(at a dose of 20 mg/day) could reduce total cholesterol
concentrations to between 1.20 and 2.64 mmol/L. Despite the
lowerefficacyofdarkchocolateconsumption,shorttermclinical
trials thus far have shown low (if any) adverse events and high
rates of compliance. The blood pressure lowering and total
cholesterol lowering effects of dark chocolate consumption
provide a non-drug treatment option, either alone or in
combination with therapeutic interventions.
Limitations of the study
A few limitations to our analyses warrant mention. Firstly, no
algorithm for risk prediction of cardiovascular events in a
population with metabolic syndrome is available. The
Framingham algorithm was developed from a healthy 20th
century cohort and therefore may under-predict events in a
higher risk population. Other available algorithms for higher
risk populations, such as those of the United Kingdom
Prospective Diabetes Study (intended specifically for use in
people with diabetes), may conversely over-predict risk. The
Framingham algorithm was chosen for the present analyses as
it was likely to represent a conservative estimate of the effects
of dark chocolate consumption.
Asecondlimitationpertainedtotheestimationsofriskofdeath
after a non-fatal cardiovascular event. Owing to limitations in
the availability of subgroup specific data, we assumed the risks
ofdyingfrombothcardiovascularandnon-cardiovascularcauses
to be the same for all those with established cardiovascular
disease. We also assumed that the risk of dying from
non-cardiovascular related causes was the same for those with
cardiovasculardiseaseaswithout.Thisisofcoursenotaccurate,
as risk of dying is influenced not only by the type and severity
of the initial non-fatal event but also by other risk factors that
may increase mortality risk. The likely consequence was an
underestimation of risk of death among those with
cardiovascular disease, and again reflected our erring on the
side of conservatism.
We did not consider several other effects of dark chocolate. On
the one hand, dark chocolate or cocoa polyphenols have been
shown to generate beneficial metabolic effects (including
decreasedlowdensitylipoproteincholesterollevels,
29increased
high density lipoprotein cholesterol levels,
30 and increased
insulin sensitivity
31); improve endothelial function and cause
anti-inflammatoryandantithromboticeffects
32 33;reducestress
34;
andimprovemood.
35Conversely,darkchocolatecontainssugar
andimposesanadditionalcaloricandglycaemicload
32thatmay
need to be accounted for by modification of the background
diettoreducetheriskofweightgain(asusuallyoccursindietary
interventionstudies).Whileinmanycasesthiscouldbeachieved
through substitution of chocolate for other snack foods in the
diet, we were not able to account for other dietary changes in
the modelling analyses. However, recent studies have found
thatdarkchocolatealsoincreasessatiety,
33potentiallycountering
the additional caloric and carbohydrate load imposed by the
dark chocolate.
A further limitation to our analyses was the assumption that the
benefits of dark chocolate, observed in short term trials,
extended to 10 years. This assumption is common in any long
term therapy, including drug treatment. Heterogeneity among
treatment effects was also noted, owing to one trial in the
meta-analysisbeingastatisticaloutlier.Weexcludedthisstudy
in a revised meta-analysis (which improved homogeneity), and
derived a systolic blood pressure reducing effect of −3.0 mm
Hg (95% confidence interval −4.31 to −2.38 mm Hg). When
applied to the model, the revised potential monies available for
preventionwasonlymarginallydecreased,to$A32(interquartile
range $A21-43; $34, $22-45).
Finally, it is acknowledged that the present analysis assumed
compliance rates with dark chocolate ranging from 80% to
100%. The studies contributing to the recent meta-analysis
9 11
reportednosideeffectsandalsooptimalcompliance.However,
one study noted that 20% of participants did not consider dark
chocolate to be an acceptable long term treatment option.
36
Conclusions and implications of study
findings
The findings of this study suggest that the blood pressure
loweringandlipideffectsofplaindarkchocolatecouldrepresent
an effective and cost effective strategy for the prevention of
cardiovasculardiseaseinpeoplewithmetabolicsyndrome(and
no diabetes). Chocolate benefits from being by and large a
pleasant, and hence sustainable, treatment option. Evidence to
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at least 60-70% cocoa, or formulated to be enriched with
polyphenols.
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RESEARCHWhat is already known on this topic
Dark chocolate has antihypertensive, anti-inflammatory, antithrombotic, and metabolic effects
Short term trials have shown that dark chocolate consumption can potentially reduce systolic blood pressure by 5 mm Hg (interquartile
range 2-8 mm Hg) and total cholesterol concentration by 0.21 mmol/L (0.05-0.36 mmol/L)
What this study adds
A modelling analysis predicted that dark chocolate consumption in populations at high risk of cardiovascular disease could potentially
avert cardiovascular events over the long term owing to its antihypertensive and metabolic effects
The model also suggested that $A40 (£25; €31; $42) could be cost effectively spent per person per year on prevention strategies using
dark chocolate
This best case analysis suggests that dark chocolate/cocoa consumption with a polyphenol content of 500-1000 mg would be an effective
and cost effective primary prevention strategy for those with multiple cardiovascular disease risk factors
Tables
Table 1| Characteristics of trials included in meta-analyses from which the blood pressure lowering and cholesterol lowering effects of
dark chocolate therapy were drawn
Polyphenols per daily
dosage (mg) Dosage (g/d) Duration (days) Study design: therapy Study
Systolic blood pressure effects in
hypertension trials:
500 100 14 Crossover: dark/white chocolate Taubert et al
37
500 100 15 Crossover: dark/white chocolate Grassi et al
31
30 6.3 126 (18 weeks) Parallel: dark/white chocolate Taubert et al
6
1008 100 15 Crossover: dark/white chocolate Grassi et al
38
900 (control: 28) 31 cocoa 14 Crossover: high flavonol cocoa/low flavonol
drink
Muniyappa et al
39
Cholesterol effects in cardiovascular
risk trials:
88 100 15 Crossover: dark/white chocolate Grassi et al
31
30 6.3 126 (18 weeks) Parallel: dark/white chocolate Taubert et al
6
963 (control: 75) 54 30 Crossover: high flavonol cocoa/low flavonol
drink
Balzer et al
40
900 (control: 28) 31 cocoa 14 Crossover: high flavonol cocoa/low flavonol
drink
Muniyappa et al
39
Only significant effects shown in meta-analyses were included in the model, therefore blood pressure effects were limited to those in people with hypertension
and cholesterol effects to those at risk of cardiovascular disease (people with diabetes or hypertension, or both).
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RESEARCHTable 2| Data inputs used in Markov model of the effect and cost effectiveness of dark chocolate consumption in a population with metabolic
syndrome free of cardiovascular disease and diagnosed diabetes
Sources Uncertainty analysis Base case value Data input
Ried 2010
9 2 to 8 5 Reduction in systolic blood pressure (mm Hg)
Jia 2010
11 0.05 to 0.36 0.21 Reduction in total cholesterol (mmol/L)
Annual cost data ($A)
Myocardial infarction:
Salkeld 1997
19 21 229 to 25 947 23 588 Year 1 care
Salkeld 1997
19 2089 to 2553 2321 Ongoing care
Stroke:
Salkeld 1997
19 24 342 to 29 752 27 047 Year 1 care
Salkeld 1997
19 6145 to 7511 6828 Ongoing care
Walker 2010
20 13 280 to 16 231 14 756 Cardiovascular death
$A1.00 (£0.62; €0.77; $0.99).
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RESEARCHTable 3| Baseline characteristics of modelled population (n=2013): metabolic syndrome, free of cardiovascular disease or diabetes,
prehypertensive/hypertensive, and not receiving any antihypertensive therapy from Australian Diabetes, Obesity and Lifestyle study.
Values are means (standard deviations) unless stated otherwise
Values Population characteristics
1104 (54.8) No (%) men
909 (45.2) No (%) women
53.6 (13.1) Age (years)
141.1 (13.8) Systolic blood pressure (mm Hg)
6.1 (1.1) Total cholesterol (mmol/L)
1.2 (0.3) High density lipoprotein cholesterol (mmol/L)
34.3 (6.4) HbA1c (mmol/mol)
100.4 (11.4) Waist circumference (cm)
29.9 (4.8) Body mass index (kg/m
2)
260 (13.0) Smoking (%)
408 (20.3) Parental history of diabetes (%)
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RESEARCHFigure
Markov model of effect of dark chocolate consumption versus no consumption and its effects on cardiovascular outcomes
in a population with metabolic syndrome
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